Study on the synergistic activity of G-749 and colistin against Escherichia coli
Journal of Antimicrobial Chemotherapy · 2026
DOI: 10.1093/jac/dkag301 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2026. Verfasst von Tianle Pan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China. Hauptthemen laut MEDLINE: Colistin, Drug Synergism, Escherichia coli, Anti-Bacterial Agents. Die Arbeit nennt 22 Literaturangaben. Gefördert von: Key Research and Development Program of the Science and Technology Plan, Shanghai Agricultural Science and Technology Innovation Project.
Abstract (Originalsprache)
Objectives
In order to investigate the synergistic antibacterial effects of the novel FLT3 inhibitor G-749 in combination with colistin against Escherichia coli (E. coli).
Methods
The in vitro antibacterial activity of G-749 combined with colistin was evaluated by MIC using the broth microdilution method, followed by checkerboard synergy testing and time-kill assays. The in vivo efficacy was assessed in a murine thigh infection model using mcr-positive colistin-resistant strain M17GZZ15. Mechanistic studies employed propidium iodide (PI) and 4′,6-diamidino-2-phenylindole (DAPI) staining to evaluate bacterial membrane integrity and nucleic acid content. The pharmacokinetic profile of G-749 was characterized in mice after a single oral dose of 100 mg/kg body weight.
Results
G-749 significantly potentiated colistin activity, reducing the MIC of colistin by 16- to 64-fold against susceptible E. coli ATCC25922 and by 8- to 32-fold against the resistant strain M17GZZ15. Time-kill assays revealed rapid bactericidal effects within 4 h. In the murine thigh infection model, the combination therapy significantly reduced bacterial burdens compared with monotherapy (P < 0.01). Mechanistic investigations showed enhanced PI uptake, indicating increased membrane permeability, and diminished DAPI fluorescence, suggesting intracellular nucleic acid leakage. Pharmacokinetic profiling of G-749 yielded a Cmax of 17.94 mg/L at Tmax 0.67 h, an AUC0-24 of 44.91 mg·h/L, and an elimination half-life of 3.34 h.
Conclusions
These findings establish G-749 as a potent colistin adjuvant that acts primarily by augmenting membrane disruption, with oxidative stress and energy suppression potentially contributing at higher concentrations, thereby improving antibacterial efficacy against Gram-negative bacteria. This multi-mechanistic and concentration-dependent synergistic profile offers a promising strategy to combat multidrug-resistant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Shanghai Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Shanghai 200241, China.
- China College of Animal Science and Technology, Yangtze University, Jingzhou, Hubei 434023, China.
Förderung
- Key Research and Development Program of the Science and Technology Plan
- Shanghai Agricultural Science and Technology Innovation Project
Zitieren
APA
Pan, T., Liu, L., Huang, R., Wang, M., Fei, C., & Liu, Y. (2026). Study on the synergistic activity of G-749 and colistin against Escherichia coli. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkag301
Vancouver
Pan T, Liu L, Huang R, Wang M, Fei C, Liu Y. Study on the synergistic activity of G-749 and colistin against Escherichia coli. Journal of Antimicrobial Chemotherapy. 2026. doi:10.1093/jac/dkag301
BibTeX
@article{Pan2026,
author = {Pan, Tianle and Liu, Lian and Huang, Ruyue and Wang, Mi and Fei, Chenzhong and Liu, Yingchun},
title = {Study on the synergistic activity of G-749 and colistin against Escherichia coli},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2026},
doi = {10.1093/jac/dkag301}
}
EUVIMED